5-IP7, diphosphoinositol pentakisphosphate; ALT, alanine aminotransferase; AST, aspartate transaminase; AUC, area under curve; Akt; BAT, brown adipose tissue; CD, chow-diet; CPT1a, carnitine palmitoyltransferase I; Cidea, cell death activator-A; DIO, diet-induced obesity; Diabetes; EE, energy expenditure; EWAT, epididymal adipose tissue; Energy expenditure; GSK3, glycogen synthase kinase; GTT, glucose tolerance test; H&E, hematoxylin and eosin; HFD, high-fat diet; HPLC, high performance liquid chromatography; IP6K; IP6K, Inositol hexakisphosphate kinase; IP6K1-KO, IP6K1 knockout; ITT, insulin tolerance test; IWAT, inguinal adipose tissue; Inositol pyrophosphate; Obesity; PCR, polymerase chain reaction; PGC1α, PPAR coactivator 1 alpha; PKA, protein kinase A; PPARγ, peroxisome proliferator-activated receptor gamma; PRDM16, PR domain containing 16; Pro-TNP, TNP treatment for protection against DIO; Q-NMR, quantitative nuclear magnetic resonance; QRT-PCR, quantitative reverse transcription polymerase chain reaction; RER, Respiratory exchange ratio; RWAT, retroperitoneal adipose tissue; Rev-TNP, long-term TNP treatment for reversal of DIO; RevT-TNP, Long-term TNP treatment for reversal of DIO at thermoneutral temperature; S473, serine 473; S9, serine 9; SREV-TNP, short-term TNP treatment for reversal of DIO; T2D, type-2 diabetes; T308, threonine 308; TNP, [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine]; UCP-1/3, uncoupling protein 1/3; VO2, volume of oxygen consumption; WAT, white adipose tissue